Philips highlights cardiology portfolio

Philips Medical Systems highlighted its new iE33 echocardiography system, the Allura FD20 flat detector x-ray system and the Allura 3D Coronary Angiography heart imaging tool at this week's American Heart Association (AHA) Scientific Sessions in New Orleans, La.

The iE33 features integrated 3D cardiac quantification software for measurement of the left ventricle volume and ejection fraction, key indicators of heart health. The system also can analyze wall motion in 17 different segments of the heart simultaneously, so physicians can identify areas of dysfunction and make treatment decisions, Philips said.

The system's new Explora family of transducers includes the S5-1 with PureWave crystal technology. The iE33 system is compatible with Philips Xcelera cardiology information solutions portfolio, which is able to accept, view, navigate 3D volume, quantify, and archive the 3D DICOM images generated by the iE33. Also, customers currently working with Philips EnConcert have the opportunity to upgrade their system to Xcelera while maintaining their existing data, to take full advantage of the iE33's capabilities, according to Philips.

The iE33 features an ergonomic design that's fully adjustable, hands-free voice command, one-button automated controls for quick and consistent image acquisition between users of varying skill levels, and an easy-to-use interface, Philips said.  

The Allura Xper FD20 is powered by Philips' 2K x 2K imaging chain and captures and processes information at a resolution up to four times greater than conventional systems, according to the company. StentBoost, Philips interventional tool that provides a clear view of stent deployment in coronary arteries, is also available, allowing clinicians to immediately take corrective action, potentially eliminating the need for additional costly procedures.

Developed in collaboration with scientists at the University of Colorado Health Sciences Center, the Allura 3D-Coronary Angiography (3D-CA) software/tool provides 3D images of the coronary arteries. The Allura 3D-CA received market clearance in late September.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.